GlobeNewswire

Quoin Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2026 Financial Results
05/11/2026
– Reports Positive Interim Data from Ongoing Phase 2/3 Study of QRX003 in Netherton Syndrome; Primary and Key Secondary Endpoints Achieved Statistical Significance Versus Pre-Specified Alpha-Adjusted Target –Announces [...]
Microbot Medical® Strengthens IP Portfolio as it Continues to Establish Infrastructure to Support Future Commercialization Expansion
05/11/2026
HINGHAM, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY ® Endovascular Robotic System, today announced that the Canadian Intellectual [...]
Prenetics’ IM8 and Authentic Brands Group Announce 10-Year Exclusive Global Partnership to Create Care Bears by IM8; Authentic to Become Strategic Shareholder in Prenetics
05/11/2026
Care Bears by IM8 to launch, with great-tasting, science-backed gummy multivitamins for kids and adults in 1H 2027 Enters a global gummy supplements market projected to nearly double to ~US$47.8 billion by 2030 IM8 to [...]
Marea Therapeutics, a Subsidiary of Lisata Therapeutics, to Participate in Upcoming November Investor Conferences
05/11/2026
SOUTH SAN FRANCISCO, Calif. and LIBERTY CORNER, N.J., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Marea Therapeutics, Inc. (“Marea”), a subsidiary of Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata”), a clinical-stage [...]
SCYNEXIS Reports Third Quarter 2026 Financial Results and Provides Corporate Update
05/11/2026
Completed Phase 1 study of SCY-770, a first-in-class, highly selective, oral direct AMPK activator for the treatment of ADPKD; Phase 2 proof-of-concept trial to initiate in Q4 2026 Awarded BARDA contract providing up to [...]
Arcutis Begins Enrolling Phase 3 Study Evaluating ZORYVE® (roflumilast) Cream 0.3% in Moderate to Severe Atopic Dermatitis
05/11/2026
New INTEGUMENT-3 study to evaluate efficacy, safety, and tolerability of investigational ZORYVE® cream 0.3% in individuals with moderate to severe atopic dermatitis Study aims to expand once-daily ZORYVE cream treatment [...]
Solid Biosciences to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference
05/11/2026
CHARLESTOWN, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac [...]
MRM Health and Biocodex establish strategic partnership to strengthen future commercial supply capabilities for CORAL®-based medicines
05/11/2026
Ghent, Belgium – November 5, 2026, Nov. 05, 2026 (GLOBE NEWSWIRE) -- MRM Health and Biocodex establish strategic partnership to strengthen future commercial supply capabilities for CORAL®-based medicines Collaboration [...]
Science 37 Named 2026 “BioTechnology Innovation of the Year” for its Direct-to-Patient Clinical Trial Delivery Model
05/11/2026
The BioTech Breakthrough Award recognizes Science 37’s Direct-to-Patient Site model for expanding patient access and delivering measurable clinical trial performance nationwide MORRISVILLE, N.C., Nov. 05, 2026 (GLOBE [...]
Taysha Gene Therapies to Release Third Quarter 2026 Financial Results and Host Conference Call and Webcast on November 12
05/11/2026
DALLAS, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies [...]
SpyGlass Pharma to Participate in Upcoming Investor Conferences
05/11/2026
IRVINE, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass Pharma” or “Company”), a late-stage biopharmaceutical company, today announced that members of the executive management [...]
Ovid Therapeutics to Participate in Upcoming Investor Conferences
05/11/2026
NEW YORK, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to pioneering better, gentler medicines for brain disorders with significant unmet need, today [...]
Novastra Therapeutics Establishes Scientific Advisory Board and Appoints Senior Advisors and Head of Clinical Development
05/11/2026
Experts in immuno-oncology, medical oncology, clinical development, and regulatory affairs to guide and support advancement of OmniAntigen™ Platform (OAP) programs OAP enables systematic immune reprogramming therapy ( [...]
Verrica Pharmaceuticals to Report Third Quarter 2026 Financial Results and Provide a Corporate Update on November 12, 2026
05/11/2026
WEST CHESTER, Pa., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of [...]
Scribe Therapeutics to Participate in Upcoming Healthcare Investor Conferences
05/11/2026
ALAMEDA, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Scribe Therapeutics Inc. (“Scribe Therapeutics” or “the Company”) (Nasdaq: SCTX), a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR [...]
PharmAla Signs Agreement and Initiates R&D with Corealis Pharma for GMP Manufacturing of its patented ALA-002 Drug Product
05/11/2026
TORONTO, Nov. 05, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. ("PharmAla" or the "Company") (CSE: MDMA) (OTCQB: MDXXF), a biotechnology company focused on the research, development and manufacturing of MDXX- [...]
Shattuck Labs Reports Third Quarter 2026 Financial Results and Recent Business Highlights
05/11/2026
– Initiated the RECEPTIVE-CD1 Phase 2b clinical trial of SL-325 in Crohn’s disease; 12-week induction data expected in the first half of 2028 – – Announced RECEPTIVE-HS1 Phase 2 clinical trial of SL-325 in hidradenitis [...]
Baird Medical and Alpmed Announce FDA 510(k) and EU CE Submissions for Irreversible Electroporation (IRE) System
05/11/2026
510(k) Application to U.S. Food and Drug Administration and Application for European Union Certification Submitted in Fourth Quarter 2026 NEW YORK, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Baird Medical Investment Holdings [...]
Altimmune to Report Third Quarter 2026 Financial Results and Provide Business Update on November 12, 2026
05/11/2026
MORRISTOWN, N.J., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a biopharmaceutical company advancing pemvidutide, an investigational balanced 1:1 glucagon/GLP-1 receptor agonist, in serious liver [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum